Medartis Holding AGXSWX:MED -0.55%76 EBITDA Margin % is 16.41% as of Dec. 2025, which is 23% above its 10-year median of 13.32. GuruFocus rates XSWX:MED with a GF Score™ of 76/100 and a GF Value™ of CHF105.61 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Medartis Holding AG ranks better than 69.98% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medartis Holding AG's EBITDA for the
six
months ended in Dec. 2025 was CHF24.0 Mil. Medartis Holding AG's Revenue for the
six
months ended in Dec. 2025 was CHF146.2 Mil. Therefore, Medartis Holding AG's EBITDA margin for the quarter that ended in Dec. 2025 was 16.41%.
Medartis Holding AG (XSWX:MED) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medartis Holding AG EBITDA Margin % Related Terms
Medartis Holding AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medartis Holding AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MED vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Medartis Holding AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medartis Holding AG EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medartis Holding AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medartis Holding AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medartis Holding AG (XSWX:MED) has a EBITDA Margin % of 16.41% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medartis Holding AG and its competitors. This is 23% above median its historical median of 13.32. Over the past decade, Medartis Holding AG's EBITDA Margin % has ranged from 6.40 to 16.98. According to the industry distribution chart, Medartis Holding AG ranks #245 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 30%.
Is Medartis Holding AG's EBITDA Margin % too high?
Medartis Holding AG's current EBITDA Margin % of 16.41% is 23% above median its 10-year median of 13.32. Over the past 10 years, this metric has ranged from a low of 6.40 to a high of 16.98. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Medartis Holding AG's value of 16.41% is 119.5% above this industry median. Based on the distribution chart, Medartis Holding AG ranks #245 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medartis Holding AG has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medartis Holding AG ranks #245 out of 816 companies for EBITDA Margin %. This puts Medartis Holding AG in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Medartis Holding AG's value of 16.41% is 119.5% above this benchmark. Historically, Medartis Holding AG's own EBITDA Margin % has ranged from 6.40 to 16.98 over the past decade. While the company's 10-year median is 13.32 vs. the industry median of 7.48, Medartis Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medartis Holding AG's current EBITDA Margin % of 16.41% is 119.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medartis Holding AG and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medartis Holding AG's current EBITDA Margin % is 16.41%, which is 23% above median its own 10-year median of 13.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Medartis Holding AG (XSWX:MED) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF105.61, compared to a current price of CHF72.00 — trading 31.8% below its estimated fair value. The current EBITDA Margin % is 16.41%, which is 23% above median its 10-year median of 13.32 and 119.5% above the Medical Devices & Instruments industry median of 7.48. Medartis Holding AG's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medartis Holding AG (XSWX:MED), the current EBITDA Margin % is 16.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medartis Holding AG (XSWX:MED) Overvalued in 2026?
Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued.
The current stock price of CHF72.00 is trading 31.8% below its estimated GF Value™ of CHF105.61.
GuruFocus considers Medartis Holding AG to be Significantly Undervalued.
Key valuation signals for XSWX:MED:
EBITDA Margin %: 16.41% (23% above median its 10-year median of 13.32)
GF Value™: CHF105.61 vs. price of CHF72.00 (31.8% below fair value)
Industry Position: 119.5% above the Medical Devices & Instruments median (#245 of 816)
No single metric tells the full story. See the XSWX:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
76GF Score
Get the complete analysis for XSWX:MED
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MED has been successfully added to your 
